0 31

Cited 0 times in

A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study

Authors
 Sang-Cheol Bae  ;  Jinseok Kim  ;  Jung-Yoon Choe  ;  Won Park  ;  Sang-Heon Lee  ;  Yong-Beom Park  ;  Seung-Cheol Shim  ;  Shin-Seok Lee  ;  Yoon-Kyoung Sung  ;  Chan-Bum Choi  ;  So-Ra Lee  ;  HanYu Park  ;  Yongho Ahn 
Citation
 Annals of the Rheumatic Diseases, Vol.76(1) : 65-71, 2017 
Journal Title
 Annals of the Rheumatic Diseases 
ISSN
 0003-4967 
Issue Date
2017
MeSH
Adult ; Aged ; Antibodies/blood ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/immunology ; Antirheumatic Agents/pharmacokinetics* ; Antirheumatic Agents/therapeutic use* ; Arthritis, Rheumatoid/drug therapy* ; Biosimilar Pharmaceuticals/pharmacokinetics* ; Biosimilar Pharmaceuticals/therapeutic use* ; Double-Blind Method ; Drug Therapy, Combination ; Etanercept/adverse effects ; Etanercept/immunology ; Etanercept/pharmacokinetics* ; Etanercept/therapeutic use* ; Female ; Humans ; Male ; Methotrexate/therapeutic use ; Middle Aged ; Therapeutic Equivalency ; Treatment Outcome
Keywords
Anti-TNF ; DMARDs (biologic) ; Rheumatoid Arthritis
Abstract
OBJECTIVES: To evaluate equivalence in efficacy for rheumatoid arthritis (RA) and compare the safety of the biosimilar HD203 with innovator etanercept (ETN) plus methotrexate (MTX) (ClinicalTrials.gov NCT01270997). METHODS: Patients with active RA received 25 mg HD203 or ETN subcutaneously twice-weekly with MTX for 48 weeks in a phase III, multicentre, randomised, double-blind, parallel-group design. The primary end point was the proportion of patients achieving the American College of Rheumatology 20% response (ACR20) at week 24 for per-protocol study completer set (PPS). Secondary end points included ACR response criteria, ACRn, European League against Rheumatism (EULAR) response, change in Disease Activity Score 28 (DAS28), patient-reported outcomes, safety and immunogenicity. RESULTS: Of the 294 randomised patients (HD203, n=147; ETN, n=147), 233 comprised the 24-week PPS (n=115 and 118, respectively). ACR20 at week 24 was achieved by 83.48% and 81.36% of PPS patients, respectively, demonstrating equivalent efficacy within predefined margins of ±20% (treatment difference 2.12%, 95% CI -7.65% to 11.89%). Outcomes for secondary end points were consistent with the primary efficacy findings. Groups were comparable for overall incidences of treatment-emergent (all-causality) adverse events (AEs) (HD203 113 (76.9%) vs ETN 114 (78.1%) (p=0.804)), adverse drug reactions, serious AEs and discontinuations due to AEs. Few patients (HD203, n=8; ETN, n=3) tested positive for anti-drug antibodies. CONCLUSION: The study met the primary objective of demonstrating equivalent efficacy of HD203 and ETN. HD203 was well tolerated, with safety comparable with ETN in this population of patients with RA. TRIAL REGISTRATION NUMBER: NCT01270997; Results.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/161237
DOI
10.1136/annrheumdis-2015-207613
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
박용범(Park, Yong Beom)
사서에게 알리기
  feedback
Full Text
http://ard.bmj.com/content/76/1/65.long
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse